1Division of Gastroenterology, Southern California Permanente Medical Group, Los Angeles, CA, USA
2Division of Gastroenterology, Rutgers University, Robert Wood Johnson Medical School, New Brunswick, NJ, USA
3Division of Gastroenterology, Thomas Jefferson University Hospital, Philadelphia, PA, USA
4Division of Gastroenterology, Weill Cornell Medical College, New York, NY, USA
Copyright © 2020 Korean Society of Gastrointestinal Endoscopy
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflicts of Interest: Michel Kahaleh received grant support from Boston Scientific, Fujinon, EMcison, Xlumena Inc., W.L. Gore, MaunaKea, Apollo Endosurgery, Cook Endoscopy, ASPIRE Bariatrics, GI Dynamics, NinePoint Medical, Merit Medical, Olympus, and MI Tech. He is a consultant for Boston Scientific, Xlumena Inc., Concordia Laboratories Inc, ABBvie, and MaunaKea Tech. Amy Tyberg is a consultant for Endogastric Solutions. The other authors have no financial conflicts of interest.
Author Contributions
Conceptualization: Michel Kahaleh
Data curation: Ming Ming Xu, Iman Andalib, Aleksey Novikov, Enad Dawod, Moamen Gabr, Monica Gaidhane, Amy Tyberg, MK
Formal analysis: MMX, IA, AN, ED, MGab, MGai, AT, MK
Methodology: MK
Supervision: MK
Validation: MK
Writing-original draft: MMX, IA, AN, ED, MGab, MGai, AT
Writing-review&editing: MK
Characteristics | Total (n=108) | p-values |
---|---|---|
Age (range, SD) | 51.8 yr (14–90, 16.3) | |
Gender, Male (%) | 67/108 (62%) | |
PFC groups (%) | ||
Poorly organized fluid collection | 13/108 (12%) | |
Pancreatic pseudocyst | 43/108 (40%) | |
Walled-off pancreatic necrosis | 52/108 (48%) | |
Etiology | ||
Autoimmune | 2/108 | |
Medication induced | 4/108 | |
Pancreas divisum | 6/108 | |
Alcohol induced pancreatitis | 19/108 | |
Gallbladder stones induced pancreatitis | 42/108 | |
Hereditary | 1/108 | |
Hypertriglyceridemia | 5/108 | |
Idiopathic | 5/108 | |
Post surgical | 13/108 | |
Post ERCP pancreatitis | 7/108 | |
Cancer related | 3/108 | |
Trauma | 1/108 | |
Size of PFC pre-treatment | 9.2 cm (1.8–29.8) | p<0.0001 |
Size of PFC post treatment | 0.89 cm (0–10) | Mean decrease of –8.66 cm |
Recurrence rate (%) | 9/108 (8.3%) | |
Mortality rate (%) | 4/108 (3.7%) | |
Multiorgan failure | 3/4 |
Type of fluid collection | Poorly organized fluid collection | Pancreatic pseudocyst | Walled-off pancreatic necrosis |
---|---|---|---|
n=13 | n=43 | n=52 | |
Pancreatic duct leak present | 5 (38%) | 24 (56%) | 31 (60%) |
Enteral feeding conducted | 6 (46%) | 14 (33%) | 45 (86.5%) |
Pancreatic duct stenting done | 11 (85%) | 28 (65%) | 35 (67%) |
Resolution rate | 13 (100%) | 42 (100%) | 48 (92%) |
Adverse events | |||
Pseudoaneurysm bleed | 2 (5%) | ||
Bleeding needing IR embolization | |||
Gastrointestinal bleed at cystgastrostomy site | 1 (2%) | 3 (6%) | |
Pancreatic fluid collection | 1 (2%) | ||
Enterocutaneous fistula | 1 (2%) | ||
Stent migration | 1 (2%) | ||
Bowel perforation | 1 (2%) |
ERCP, endoscopic retrograde cholangiopancreatography; PFC, pancreatic fluid collection; SD, standard deviation.
IR, interventional radiology.